B-cell modulation with anti-CD79b antibodies ameliorates experimental autoimmune encephalitis in mice
Renner K, Neumayer S, Talke Y, Buchtler S, Schmidbauer K, Nimmerjahn F, Lux A, Winter F, Salewski JN, Mack M (2022)
Publication Type: Journal article
Publication year: 2022
Journal
Abstract
B cells play a major role in the pathogenesis of many autoimmune diseases like MS, rheumatoid arthritis, or systemic lupus erythematosus. Depletion of B cells with anti-CD20 antibodies is an established therapy for MS. However, total B-cell depletion will also affect regulatory B cells that are known to suppress autoimmune responses. In our studies, we describe an alternative approach based on targeting CD79b that induces only partial B-cell depletion and achieves therapeutic effects by B-cell modulation. Prophylactic and therapeutic treatment with an antibody against CD79b and also a deglycosylated variant of this antibody, lacking effector function like antibody-dependent cellular cytotoxicity or complement activation, significantly reduced the development and progression of EAE in mice. Our data show that modulation of B cells via CD79b is equally effective as almost complete B-cell depletion with anti-CD20 antibodies and may constitute an alternative approach to treat MS.
Authors with CRIS profile
Involved external institutions
Germany (DE)How to cite
APA:
Renner, K., Neumayer, S., Talke, Y., Buchtler, S., Schmidbauer, K., Nimmerjahn, F.,... Mack, M. (2022). B-cell modulation with anti-CD79b antibodies ameliorates experimental autoimmune encephalitis in mice. European Journal of Immunology. https://dx.doi.org/10.1002/eji.202149523
MLA:
Renner, Kerstin, et al. "B-cell modulation with anti-CD79b antibodies ameliorates experimental autoimmune encephalitis in mice." European Journal of Immunology (2022).
BibTeX: Download